Literature DB >> 22966320

Development of hepatocellular carcinoma in patients with chronic hepatitis C more than 10 years after sustained virological response to interferon therapy.

Keiichiro Nojiri1, Kazushi Sugimoto, Katsuya Shiraki, Satoko Kusagawa, Junichiro Tanaka, Tetsuya Beppu, Norihiko Yamamoto, Yoshiyuki Takei, Akira Hashimoto, Atsuya Shimizu, Shigeru Omori, Masahiko Tameda, Koujiro Takase.   

Abstract

The risk factors for the development of hepatocellular carcinoma (HCC) in patients who have achieved a long-term sustained viral response (SVR) to interferon (IFN) are not fully understood. This study aimed to investigate the characteristics of patients who developed HCC after 10 years of achieving SVR. We retrospectively studied 5 patients with HCC which developed more than 10 years after the termination of IFN therapy. The clinical characteristics at the induction of IFN therapy were male gender, a mean age of 51.6±9.1 years, while 2 patients were moderate alcohol consumers. None of the 5 patients were positive for either HBs Ag or anti-HBc Ab. A histological examination at the initial IFN therapy showed the activity scores to be A2 in all cases, and the fibrosis scores at least F2. The clinical parameters at the diagnosis of HCC included fluctuating transaminase levels in all cases. These levels scarcely fell below the upper limits even after SVR was achieved. In 3 patients, liver tissues were obtained at the treatment of HCC. These tissues showed marked improvement in both activities and fibroses, but severe steatosis in 1 patient. To conclude, chronic hepatitis C patients who respond to IFN therapy should undergo long-term follow-up, even after the eradication of HCV, with special attention particularly to patients who had elevated transaminase levels and steatosis.

Entities:  

Year:  2010        PMID: 22966320      PMCID: PMC3436442          DOI: 10.3892/ol_00000075

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group.

Authors:  A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita
Journal:  Hepatology       Date:  1998-05       Impact factor: 17.425

2.  Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C.

Authors:  Naoyuki Enokimura; Katsuya Shiraki; Tomoyuki Kawakita; Yukiko Saitou; Hidekazu Inoue; Hiroshi Okano; Norihiko Yamamoto; Masatoshi Deguchi; Takahisa Sakai; Shigeru Ohmori; Katsuhiko Fujikawa; Kazumoto Murata; Yasuo Niki; Takeshi Nakano
Journal:  Anticancer Res       Date:  2003 Jan-Feb       Impact factor: 2.480

3.  Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.

Authors:  Akihiro Tamori; Shuhei Nishiguchi; Susumu Shiomi; Takehiro Hayashi; Sawako Kobayashi; Daiki Habu; Tadashi Takeda; Shuichi Seki; Kazuhiro Hirohashi; Hiromu Tanaka; Shoji Kubo
Journal:  Am J Gastroenterol       Date:  2005-08       Impact factor: 10.864

4.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

Authors:  K Ikeda; S Saitoh; Y Arase; K Chayama; Y Suzuki; M Kobayashi; A Tsubota; I Nakamura; N Murashima; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

Review 5.  Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma.

Authors:  T Poynard; J Moussalli; V Ratziu; C Regimbeau; P Opolon
Journal:  Clin Liver Dis       Date:  1999-11       Impact factor: 6.126

6.  Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.

Authors:  N Hirashima; M Mizokami; E Orito; T Koide; I Itazu; K Kumada; K Sakakibara; H Kano; J Y Lau
Journal:  J Gastroenterol Hepatol       Date:  1996-10       Impact factor: 4.029

7.  Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients.

Authors:  S Kobayashi; T Takeda; M Enomoto; A Tamori; N Kawada; D Habu; H Sakaguchi; T Kuroda; K Kioka; S R Kim; T Kanno; T Ueda; M Hirano; S Fujimoto; H Jomura; S Nishiguchi; S Seki
Journal:  Liver Int       Date:  2007-03       Impact factor: 5.828

Review 8.  Therapy of hepatitis C.

Authors:  M W Fried; J H Hoofnagle
Journal:  Semin Liver Dis       Date:  1995-02       Impact factor: 6.115

9.  Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis.

Authors:  Mika Kurokawa; Naoki Hiramatsu; Tsugiko Oze; Kiyoshi Mochizuki; Takayuki Yakushijin; Nao Kurashige; Yuko Inoue; Takumi Igura; Kazuho Imanaka; Akira Yamada; Masahide Oshita; Hideki Hagiwara; Eiji Mita; Toshifumi Ito; Yoshiaki Inui; Taizo Hijioka; Harumasa Yoshihara; Atsuo Inoue; Yasuharu Imai; Michio Kato; Shinichi Kiso; Tatsuya Kanto; Tetsuo Takehara; Akinori Kasahara; Norio Hayashi
Journal:  Hepatol Res       Date:  2009-01-16       Impact factor: 4.288

10.  Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C.

Authors:  Sarah Maylin; Michelle Martinot-Peignoux; Rami Moucari; Nathalie Boyer; Marie-Pierre Ripault; Dominique Cazals-Hatem; Nathalie Giuily; Corinne Castelnau; Ana Carolina Cardoso; Tarik Asselah; Cyrille Féray; Marie Hélène Nicolas-Chanoine; Pierre Bedossa; Patrick Marcellin
Journal:  Gastroenterology       Date:  2008-05-21       Impact factor: 22.682

View more
  9 in total

Review 1.  Chemoprevention of hepatocellular carcinoma in patients with hepatitis C virus related cirrhosis.

Authors:  Gianni Testino; Paolo Borro
Journal:  World J Hepatol       Date:  2013-10-27

2.  Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?

Authors:  Gino S Albines; Alicia Mesa; Nelson Fuentes-Martínez; Ramón Pérez; Julieta Fernández-Molina; Manuel Rodríguez; María Varela
Journal:  Dig Dis Sci       Date:  2014-10-15       Impact factor: 3.199

Review 3.  Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma.

Authors:  Jinah Choi; Nicole L B Corder; Bhargav Koduru; Yiyan Wang
Journal:  Free Radic Biol Med       Date:  2014-05-06       Impact factor: 7.376

Review 4.  Pathogenesis and significance of hepatitis C virus steatosis: an update on survival strategy of a successful pathogen.

Authors:  Amedeo Lonardo; Luigi Elio Adinolfi; Luciano Restivo; Stefano Ballestri; Dante Romagnoli; Enrica Baldelli; Fabio Nascimbeni; Paola Loria
Journal:  World J Gastroenterol       Date:  2014-06-21       Impact factor: 5.742

Review 5.  Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.

Authors:  Yuichi Yoshida; Miki Yonezawa; Takuya Okamoto; Yudai Fujiwara; Akiko Suzuki; Yuji Suzuki; Kei Endo; Keisuke Kakisaka; Takayoshi Oikawa; Hidekatsu Kuroda; Akio Miyasaka; Yasuhiro Takikawa
Journal:  Clin J Gastroenterol       Date:  2018-10-19

Review 6.  NAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic Manifestations.

Authors:  Luigi Elio Adinolfi; Luca Rinaldi; Barbara Guerrera; Luciano Restivo; Aldo Marrone; Mauro Giordano; Rosa Zampino
Journal:  Int J Mol Sci       Date:  2016-05-25       Impact factor: 5.923

7.  HEPATOCELLULAR CARCINOMA IN A NON-CIRRHOTIC PATIENT WITH SUSTAINED VIROLOGICAL RESPONSE AFTER HEPATITIS C TREATMENT.

Authors:  Angelo Alves de Mattos; Patrícia dos Santos Marcon; Fernanda Schild Branco de Araújo; Gabriela Perdomo Coral; Cristiane Valle Tovo
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-12       Impact factor: 1.846

8.  Prediction of the Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients after Sustained Virological Response by Aspartate Aminotransferase to Platelet Ratio Index.

Authors:  Keol Lee; Dong Hyun Sinn; Geum-Youn Gwak; Hyun Chin Cho; Sin-Ho Jung; Yong-Han Paik; Moon Seok Choi; Joon Hyeok Lee; Kwang Cheol Koh; Seung Woon Paik
Journal:  Gut Liver       Date:  2016-09-15       Impact factor: 4.519

9.  Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome.

Authors:  Omar A Saldarriaga; Bradley Dye; Judy Pham; Timothy G Wanninger; Daniel Millian; Michael Kueht; Benjamin Freiberg; Netanya Utay; Heather L Stevenson
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.